← All trials
NCT06781073
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 6, 2017
- Primary completion
- Nov 25, 2024
- Completion date
- Dec 6, 2024
- First posted
- Jan 17, 2025
- Last posted
- Jan 17, 2025
- Enrollment
- 118
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Biotech Pharmaceutical Co., Ltd.Lead sponsor
- Chinese Academy of Medical SciencesOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.